CV disease events and economic outcomes | Polypill | Monocomponents | Difference (% reduction/gain) |
---|---|---|---|
ACS events | 61.06 | 75.31 | −14.25 (−21.9) |
Revascularisation (unplanned and unrelated to other CV events) | 104.49 | 120.76 | −16.26 (−15.5) |
Congestive heart failure with hospitalisation | 32.35 | 33.86 | −1.51 (−5.2) |
Stroke | 23.20 | 28.90 | −5.70 (−22.8) |
CV death | 54.62 | 64.19 | −9.57 (−17.3) |
Total LY (discounted) | 6338.57 | 6307.69 | 30.88 (0.5) |
Total QALY (discounted) | 5278.46 | 5248.92 | 29.54 (0.6) |
Drug costs (discounted) | £790 229 | £326 701 | £463 528 (141) |
Cost of acute CV events and deaths (discounted) | £2 064 865 | £2 195 567 | −£130 702 (−6.0) |
Cost of patient management (discounted) | £1 139 719 | £1 230 203 | −£90 484 (−7.4) |
Total costs (discounted) | £3 994 814 | £3 752 473 | £242 341 |
ICER (discounted) | – | – | £8205 per QALY |
ACS, acute coronary syndrome; CV, cardiovascular; ICER, incremental cost-effectiveness ratio; LY, life-years; QALYs, quality-adjusted life-years.